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Abstract: Repair and regeneration of disorders affecting cardiac and pulmonary tissues through
tissue-engineering-based approaches is currently of particular interest. On this matter, different
families of bioactive glasses (BGs) have recently been given much consideration with respect to
treating refractory diseases of these tissues, such as myocardial infarction. The inherent properties
of BGs, including their ability to bond to hard and soft tissues, to stimulate angiogenesis, and
to elicit antimicrobial effects, along with their excellent biocompatibility, support these newly
proposed strategies. Moreover, BGs can also act as a bioactive reinforcing phase to finely tune
the mechanical properties of polymer-based constructs used to repair the damaged cardiac and
pulmonary tissues. In the present study, we evaluated the potential of different forms of BGs, alone
or in combination with other materials (e.g., polymers), in regards to repair and regenerate injured
tissues of cardiac and pulmonary systems.
Keywords: bioactive glasses; scaffold; angiogenesis; soft tissue engineering; cardiac regeneration;
lung tissue engineering
1. Introduction
From a medical point of view, disorders related to heart and pulmonary systems are considered
as life-threatening pathologic conditions due to the high mortality rate [1,2]. This rate has been
continuously growing as result of increased smoking and tobacco use, physical inactivity, and
overweight and obesity [3]. Up to now, several approaches have been proposed and applied
to treat the related disorders such as organ transplantation [4]. However, there are a couple of
difficulties with regards to heart and lung transplantation, including antibody-mediated arterial
lesions, antibody-mediated rejection, and infection [5–7]. With reference to these conditions, modern
therapies have emerged in the effort to remove or at least partially overcome these complications.
As advanced approaches, tissue engineering-based therapies have been considered for treating
various disorders related to heart and pulmonary system [8–10]. To develop optimal tissue substitutes
for the aforesaid tissues, different cells and biomaterials have been evaluated and used. From a
cellular point of view, the use of adult stem cells has achieved a lot of attention [11,12]. As an
illustration, it has been shown that transplantation of adult bone-marrow-derived cells to patients
with myocardial infarction results in a statistically significant improvement in left ventricular ejection
fraction (LVEF) [13]. From the perspective of the biomaterials, polymers are used more than other
“rigid” materials (e.g., metals and ceramics) because of the soft texture of both heart and lung
Materials 2017, 10, 1429; doi:10.3390/ma10121429 www.mdpi.com/journal/materials
Materials 2017, 10, 1429 2 of 17
tissues [14–16]. However, these polymeric matrices need to be reinforced by other substances to
accelerate repair and regeneration processes. For example, improving the transportation of nutrients
and oxygen by adding angiogenesis-inducing materials to polymers is considered as one of the
most promising strategies proposed for accelerated tissue reconstruction [17]. In the field of tissue
engineering, various methods have been proposed and developed to stimulate angiogenesis; in this
regard, one of the most recent and promising approaches involves the use of bioactive glasses (BGs) [18].
As previously mentioned in the literature, the strategies of inducing angiogenesis via biomaterials
are feasible and effective and allow overcoming the limitations of “biological” approaches based on
recombinant DNA technology, such as tumorigenicity and prolonged protein expression [19].
BGs have gained much attention in the field of tissue engineering and regenerative medicine
over the last decades due to their highly attractive properties such as great biocompatibility and
bioactivity [20]. These synthetic biomaterials were firstly discovered by Larry Hench and coauthors
at the University of Florida in 1969 [21]. Although the first developed BG, the well-known 45S5
Bioglass®, was synthesized using a melt-quench route, later the sol-gel method was also used as an
alternative approach to synthesize various types of new BG compositions [22]. Based on the glass
network former, BGs can be categorized as silicate-based glasses, borosilicate and borate-based glasses,
and phosphate-based glasses; basic compositions can be doped with metallic ions eliciting specific
therapeutic effects once released in situ. Looking at the microstructure, “bulk” (i.e., non-porous) or
inherently mesoporous glasses can be produced [23–25]. Nowadays, BGs are recognized as the second
generation of biomaterials with the ability to bond to the living tissues [26]. Many in vitro and in vivo
studies have been conducted on BGs to determine their potential for the reconstruction of different parts
of human body, especially in orthopedic and dental applications [27,28]. Given the many satisfactory
results, several types of BG-based products currently exist in the market, such as 45S5 Bioglass®,
which are being used for hard tissue substitution to heal bony damages and defects in orthopedics and
dentistry [29]. The main idea of using BGs for orthopedic applications comes from their ability to bond
to bone tissue (high bioactivity) as well as osteoconduction and osteoinduction [30,31]. As previously
mentioned in the literature [32,33], the release of various ions from the BGs structure into the biological
environment influences cell response at the genetic level and, therefore, dictates their effects on the
living cells and tissues (see Table 1).
Table 1. The main ions released from BGs considered for soft tissue engineering (adapted from Naseri et al. [34]).
Element Effects References
Si -Promotes neovascularization.-Stimulates collagen type I formation. [35,36]
Ca -Promotes the migration and proliferation of epidermal cells.-Accelerates blood-clotting. [37]
B -Stimulates vascularization and angiogenesis.-Increases RNA synthesis in fibroblasts. [38,39]
Cu -Stimulates angiogenesis.-Antimicrobial property. [40–43]
Ag+ -Anti-inflammatory property.-Antimicrobial property. [44–46]
Zn
-Stimulates angiogenesis.
-Enhances nerve regeneration.
-Anti-inflammatory property.
-Enhances wound healing processes.
[47–49]
Ga -Antimicrobial property. [50]
Although BGs have been used in the field of bone reconstruction, there are still some critical
limitations for their widespread use, such as high brittleness and low compressive strength [51].
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Therefore, a new trend has recently emerged among researchers to use these synthetic biomaterials
for soft tissue regeneration [52]. In addition to inducing angiogenesis, there exist some additional
reasons supporting the idea that BGs are suitable for soft tissues healing. For instance, it has been
well documented that BGs are able to inhibit the growth of Gram-positive and Gram-negative
bacteria [53,54]. This bactericidal activity is related to increasing local pH of the environment and
generating reactive oxygen species (ROS) dictated by the release of ions (e.g., zinc) from the BG
structure [55].
More recently, the use of BGs has been extended to other soft tissues including cardiac and
pulmonary systems [56]. Similar to other soft tissues, the angiogenic effects of these relatively
inexpensive materials are favorable for accelerating the healing procedures. From a general viewpoint,
bonding of BGs to tissues is governed by dissolution and precipitation reactions at the implant surface
consequent to contact with physiological fluids such as human plasma [21,57]. It is known that
collagenous components of soft tissues are able to attach to BG surfaces, and it is also important to
notice that progenitor cell populations in the surrounding tissues can partially affect the bonding and
rate of regeneration [58].
In this review, which is dedicated to the memory of Prof. Dame Julia Polak [59] (see the
Acknowledgements), we aim to present the potential of BGs as effective materials to accelerate
the regeneration of cardiac and pulmonary tissues also through stimulation of angiogenesis (Figure 1).
For this purpose, we have collected and shortly discussed the existing literature about the BGs applied
for regenerative strategies of the two aforementioned tissues, highlighting the critical issues and the
challenges for future research.
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2. Applications in Cardiac Tissue Engineering
Myocardial Infarction (MI), commonly known as a heart attack, is one of the most common
cardiovascular disorders resulting in many deaths globally every year [60]. This disorder is caused
by the blockage of the coronary arteries supplying the myocardium. The irreversible necrosis of
heart muscle is the result of MI which needs to be repaired [61]. It has been previously identified
that the human cardiomyocytes could not regenerate the damaged sites after MI [62]. Therefore,
tissue engineering-based constructs such as injectable scaffolds (e.g., hydrogels) and engineered
cardiac patches are being increasingly investigated and developed as effective tools to regenerate
the damaged tissue [63,64]. As depicted in Figure 2, cardiac tissue engineering combines isolated
functional cardiomyocytes and a biodegradable or non-degradable biomaterial to repair diseased heart
muscle; a comprehensive overview on the issues and challenges associated to this research topic was
provided by Chen et al. [65].
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BGs were recently claimed as suitable materials for cardiac tissue engineering, especially in the
form of nanoparticles in combination with biocompatible polymers acting as soft matrices (Table 2).
The use of nano-sized BGs has recently increased and is now being extensively investigated in
biomedicine [67–69]. The reasons are related to their high surface area and bioactivity, surface effects
and biocompatible ion dissolution products that can also promote therapeutic effects in vitro and
in vivo [70–72]. Moreover, nano-scale BGs can be easily dispersed in various polymeric systems,
which make them proper materials to fabricate high-added-value composites for use in soft tissue
engineering applications.
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Table 2. Summary of the studies performed to evaluate the usability of BGs for heart tissue engineering.
Materials
In Vitro/In Vivo Tests Remarks References
BG Name and Composition Polymeric Matrix
45S5 Bioglass®
(45SiO2-24.5CaO-24.5Na2O-6P2O5 wt %)
melt-derived particles
Poly(glycerol sebacate)
Human ESC derived
cardiomyocytes -Promoting cell differentiation [73]
Fibroblasts -Non-toxic
45S5 Bioglass®
(45SiO2-24.5CaO-24.5Na2O-6P2O5 wt %)
melt-derived particles
Gelatin-collagen hydrogel
Endometrial stromal
Stem cells (EnSCs)
-Inducing differentiation into
cardiomyocytes
-Increasing VEGF expression [74]
L929 cells -Good biocompatibility
45S5 Bioglass®
(45SiO2-24.5CaO-24.5Na2O-6P2O5 wt %)
melt-derived particles
Silicone elastomer Primary fibroblasts -Improving mechanical properties-Improving cytocompatibility [75]
Sol-gel BG nanoparticles
(60SiO2-35CaO-5P2O5 mol %)
Gelatin/hyaluronic acid Oral administration torats
-No remarkable change in the
morphology of heart tissue [76]
In the effort to prepare a heart patch, Chen et al. developed a series of elastomeric nanocomposites
comprising a soft elastomer (poly(glycerol sebacate), PGS) and nanoparticles of 45S5 Bioglass®
(BG concentrations ranging from 0 to 10 wt %), from which alkaline cations were released upon
soaking in aqueous media [73]. PGS has a range of drawbacks including limitations in mechanical
properties, cytotoxicity caused by the acidic degradation products (at least in some types of PGS)
and degradation kinetics that are too fast in vivo to provide sufficient mechanical support to the
regenerated tissue. The glass was incorporated into the polymer to decrease the acidity resulted from
the degradation of PGS without severely compromising its compliance. This could effectively improve
the biocompatibility of the developed PGS–nanoBioglass® (<5 wt %) composites. A mechanical
improvement was also reported by the authors in the samples containing 45S5 Bioglass® nanopowders
that could allow the compliance of the constructs to satisfy the mechanical requirements of biomaterials
applied in cardiac tissue engineering applications. This positive effect has been previously reported by
other researchers that showed that the combination of nano-scale BGs with biopolymers is a good idea
to improve their mechanical properties [77]. The authors reported the in vitro tests using fibroblasts
and human endometrial stromal cell (ESC)-derived cardiomyocytes (hESC-CM), and their results
confirmed that the PGS–nanoBioglass® composites can enhance biocompatibility in comparison to
the samples without glass particles. Moreover, beating rates for hESC-CM cultured in a medium
containing PGS–nanoBioglass® were similar to those of cells cultured in the standard culture medium
at different time points, thus indicating that the nanocomposites do not inhibit the functional activity
of the cells. The authors finally concluded that the nanocomposites are appropriate candidates for the
development of palliative treatment of congestive heart failure through the cardiac patch strategy.
The same research group also developed a set of PGS-based elastomeric composites containing
micrometric 45S5 Bioglass® fillers (5 µm-sized particles) [78]. In addition to much improved
cytocompatibility due to the buffering effect of 45S5 Bioglass® in preventing the rapid drop of
pH through the release of alkaline ions (as already observed in [73]), these PGS-based composites
demonstrated attractive mechanical properties including an increment of the elongation at break from
160% to 550% and an enhancement of the Young’s modulus from 0.38 to 1.62 MPa. It was also noted
that the addition of 45S5 Bioglass® in the composites mitigated the drop of the elastic modulus in
a physiological environment with respect to PGS alone; interestingly, after the drop in the elastic
modulus—which still occurred—the composites exhibited mechanical stability over an extended
period. This last finding is a crucial feature of the new composites because they can provide reliable
mechanical support to damaged soft tissues during the late stage of the healing process.
In a very recent study by Taimoor et al. [79], novel electrically conductive polyaniline (PANI)/PGS
composites were proposed as biocompatible scaffolds for cardiac tissue engineering and it was
observed that the addition of PANI to PGS had a similar effect to that of 45S5 Bioglass® in mitigating
the drop in pH while material degradation occurs [78].
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As previously mentioned, the ionic dissolution products of BGs can stimulate various cell-like
fibroblasts to secrete large amounts of angiogenic factors and cytokines resulting in the infiltration of
vessels into the engineered scaffolds [80,81]. To evaluate this potential for cardiac tissue engineering
strategies, Barabadi and co-workers fabricated hydrogel-based nanocomposite scaffolds containing
BG nanoparticles for myocardial tissue engineering [74]. They explained that one of the main problems
in myocardial tissue engineering is lack of functional vessels which ultimately results in a low
survival rate of engineered tissues/injected cells [74]. Thus, they first synthesized sol-gel based BGs
consisting of 45% SiO2, 24.5% CaO, 24.5% Na2O and 6% P2O5 (mol %) and then fabricated two types
of hydrogel-based scaffolds including a gelatin-collagen hydrogel (Gel/Col) and a gelatin-collagen
hydrogel containing BG nanoparticles (Gel/Col/BG). To show the effectiveness of the incorporated BGs
on angiogenesis, they evaluated the differentiation capacity of undifferentiated human ESCs within the
heterogeneous population of treated cells toward endothelial lineage (Figure 3). Their results indicated
that the expression of vascular endothelial growth factor (VEGF) was significantly increased in the
cells incubated with the conditioned media containing Gel/Col/BG scaffold compared to control.
These data indicate that BG inclusion in hydrogel scaffold promotes the expression of VEGF and
thereby enhances angiogenesis. The authors finally concluded that hydrogel scaffolds containing
BGs are suitable constructs for myocardial tissue engineering since they are biocompatible and can
promote angiogenesis.
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Cohrs and co-workers evaluated the role of incorporating of 45S5 BG nano- and micro-particles
into silicone elastomers in order to improve the characteristics of left ventricular assist device (LVAD)
drivelines [75]. The authors prepared three different nano- or micro-particles of 45S5 Bioglass® by
using flame spray synthesis and then incorporated them into medical-grade silicone elastomer to
prepare thin composite films (Figure 4). They showed that incorporation of nano-BG particles into
silicone composites led to the highest bioactivity and least swelling by 50% in the samples; however,
these nano-particles caused lower mechanical properties as well as lower cytocompatibility. In contrast,
micro-sized BG particles were twice as cytocompatible as nano-sized particles and possessed better
mechanical properties and easier handling. However, the authors of this study concluded that the
use of nano-sized glass particles in the case of driveline material for LVAD implantation was more
advantageous than micro-sized particles due to higher bioactivity and less swelling inside the body.
In vivo toxicity studies about the effect of BGs on the living heart are still rare, but preliminary results
show promise [76].
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3. Applications in Lung Tissue Engineering
Lung tissues have a poor self-regenerative ability and, thus, the only option for patients who
suffer from severe chronic obstructive pulmonary disease (COPD)—often combined with pulmonary
hypertension—is a transplant of heart and lungs [82].
The potential suitability of BGs for the repair of injured lung tissue (Table 3) was first investigated
by a joint research group coordinated by Hench and Polak in the early 2000s: In this pioneering study,
Tan et al. [83] functionalized the surface of sol-gel 58S glass scaffolds with amine or mercaptan groups
and/or laminin and studied the in vitro biocompatibility of these glass-based foams with murine lung
epithelial cells (MLE-12). The scope of the work was to find the best conditions to stimulate the growth
and proliferation of lung cells, in the effort to pose the basis for developing tissue-engineered BG
constructs for the repair of the pulmonary system. It was reported that lung cells colonized all types
of porous scaffolds also in the core and, specifically, the laminin-coated and amine-modified glass
foams were the most effective in promoting cell adhesion and growth. Sol-gel 58S glass was also found
biocompatible towards human lung adenocarcinoma A549 cells [84].
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Table 3. Summary of the studies involving the use of BGs for potential application in lung tissue engineering.
Materials In Vitro/ In Vivo
Tests Remarks ReferencesBG Name and Composition Polymeric Matrix
58S (58SiO2-36CaO-6P2O5 mol %) sol-gel
scaffold
- MLE-12 cells
-Good biocompatibility
further improved by laminin
coating or amine
functionalization
[83]
- A549 cells -Good biocompatibility [84]
45S5 Bioglass®
(45SiO2-24.5CaO-24.5Na2O-6P2O5 wt %)
melt-derived particles
PDLLA A549 cells -Dose-dependent effect [85]
PLGA L929 cells -Dose-dependent effect
[86]
Ag-doped 58S sol-gel glass
(58SiO2-(36-x)CaO-6P2O5-xAg2O, with x = 0, 1,
2 mol %)
- A549 cells -Non-toxic [87]
Fe-doped sol-gel glass (basic composition:
8.4Na2O-40CaO-39.6SiO2-12P2O5 wt % doped
with 0.2-1 wt % of Fe)
- A549 cells
-Hyperthermic effect for
possible application in lung
cancer treatment
[88]
Sol-gel BG nanoparticles
(60SiO2-35CaO-5P2O5 mol %)
Gelatin/hyaluronic acid
Oral
administration to
rats
-No remarkable change in
the morphology of lung
tissue
[76]
Polak and co-workers also explored the possibility of growing lung cells on porous poly(DL-lactic
acid) (PDLLA) scaffolds. It was reported that PDLLA was not only non-toxic to pneumocytes but
also actively supported the cell growth; these initial findings suggested the potential of this polymer
to act as an appropriate matrix for engineering of distal lung tissue [89]. Following these seminal
results, Verrier et al. [85] proposed the use of PDLLA/45S5 Bioglass® composites for lung tissue
engineering and performed in vitro biocompatibility assays with human lung carcinoma A549 cells
(Figure 5); the idea behind this work was to take the best from the two materials (polymer and glass)
that make up the porous composite. Two hours after cell seeding, a general increase of cell adhesion
according to the increased content of 45S5 Bioglass® (0 wt %, 5 wt % and 40 wt %) in the PDLLA foams
was observed, but cell proliferation studies over a period of four weeks revealed a better aptitude of
A549 cells to proliferate on scaffolds containing only 5 wt % of the glass. This result demonstrates
that the concentration of BG in tissue engineering polymer-based constructs should be always
optimized depending on the considered tissues that we want to regenerate. This dose-dependent
effect was also observed in another study by the same research group, in which poly(lactic-co-glycolic
acid) (PLGA)/45S5 Bioglass® composite tubular foam scaffolds (porosity about 93 vol %, size of
interconnected macropores in the 50–300 µm range, wall thickness within 1.5–3.0 mm) were fabricated
via thermally induced phase separation [86]; the authors proposed the use of the produced constructs
for the regeneration of tissues requiring a tubular shape scaffold (Figure 6), such as blood vessels
and trachea.
It was also reported that doping of 58S sol-gel glass with moderate amounts of silver (2 mol %
Ag2O max.) to obtain an antibacterial BG elicited no toxic effects towards A549 cells in vitro [87].
Wang et al. [88] demonstrated that the number of A549 cells can significantly decrease under the
hyperthermic effect induced by Fe-doped sol-gel BGs due to the elevation of the temperature in the
culture medium to 45 ◦C, which potentially opens new possibilities for treating lung carcinoma.
The systemic toxicity of selected BGs and BG-containing composites was evaluated in some
interesting studies carried out in vivo (rabbits). Taken together, chemical and histopathological
analyses revealed neither morphological damage nor accumulation of ions (especially silicon) released
from BGs in key organs such as brain, kidney, liver, spleen, heart, and lungs [76,90,91].
These set of results seems to actually support the fascinating possibility of using BG-based
biomaterials and scaffolds in lung tissue engineering approaches, although extensive work,
including testing with all the different cell types found in the pulmonary system, is necessary for
further advancements.
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4. Discussion and Future Challenges
This year, we are celebrating the 50th anniversary of the so-called “hypothesis of bioactive
glass” [92]: In fact, before 1967, the concept of a material that could form a direct bond to living tissues
seemed impossible. In 1985, Hench’s 45S5 Bioglass® was approved by Food and Drug Administration
(FDA) for clinical use in the repair of middle ear small bones and, since then, it has been successfully
implanted in millions of patients worldwide to repair bone and dental defects [93]. The “second life”
of BGs for potential applications in soft tissue regeneration is more recent [52,56] and, specifically, the
first reported uses of these materials for lung and cardiac tissue engineering date back to 2003 [83]
and 2010 [73], respectively. Indeed, more research still is to be carried out to support and expand the
applications of BGs in these two highly-significant fields, albeit the available results show promise.
First, we need to understand and establish clearly what is the most appropriate way to use BGs
in contact with cardiac and lung tissues. Looking at the BG-based products for bone repair that are
currently available on the market, we can found BG particles, granules, moldable putties as well as 3D
porous scaffolds that play a key role in tissue engineering approaches.
The physico-mechanical characteristics of an ideal porous scaffold for bone tissue engineering have
been established over the last 15 years taking cancellous bone as a reference tissue, and hence target
ranges for pore and strut size, permeability, stiffness and compressive strength have been proposed in
the literature [94–96]. Moving towards non-osseous applications, a crucial question is: What are the
characteristics that a scaffold for cardiac or lung tissue engineering should exhibit? A response can be
attempted, on the basis and within the frame of current knowledge. The specific physical properties that
a cardiac tissue engineering construct is expected to have are: (i) biocompatibility; (ii) ability to promote
cell adhesion and proliferation; (iii) tailored degradation rate matching the recovery rate of host soft
tissue; (iv) permeability allowing the diffusion of biomolecules; (v) suitable mechanical properties
close to those of natural tissues; (vi) contractility; and (vii) electrophysiological stability [97]. Properties
(i)–(v) can be extended to lung tissue engineering constructs, too. Especially, Properties (v) and (vi) can
be fulfilled only by using polymers, which means that BGs are suitable for these applications only if
combined with a soft polymeric matrix. Besides being useful to tune the mechanical properties of the
composite to match the features of the soft tissue to repair, BGs can play a major role from chemical
and biological viewpoints, e.g., mitigation of pH drop due to polymer degradation and improved
cytocompatibility. In this regard, there is a need for a significant amount of research to be carried out
for establishing the specific mechanisms involved in the interaction between BGs and the cells that
compose cardiac and lung tissues, just as performed for bone/dental applications in the last decades.
At present, the role of BGs in promoting cardiac and lung cell proliferation and/or differentiation
is as yet unknown. Basic cell and molecular biology studies on how BGs can actually stimulate
cardiomyocytes and pneumocytes are still to be done, and this will require a close collaboration among
glass chemists, biomaterials scientists, bioengineers, biologists, and clinicians. Future research will
also require implementation of in vitro culture and co-culture strategies for the relevant cells found in
these complex tissues that should be seeded on potentially-suitable BG-containing polymeric matrices.
Suitable in vivo models will have to be defined and standardized, too. A careful selection of appropriate
BG compositions and morphologies (e.g., micro- or nano-sized particles, and fibers) combined with
suitable soft and porous polymeric matrices are necessary to realistically consider BGs in these
particular fields.
The addition of metallic dopants to the BG composition, as well as the incorporation of growth
factors and drugs in the composites, could be considered to develop new regeneration strategies
for heart and lungs. An important limiting factor for progress in the field of regenerative medicine
utilizing ions is the risk that they can easily diffuse to other non-target cells or tissues and, thus,
stimulate unwanted responses. Mesoporous BGs (MBGs), which have been widely experimented as
carriers for therapeutic ions and biomolecules and exhibit a controlled delivery capability for such
agents [98], could partly overcome this problem by being embedded as high-added-value inclusions
in biodegradable polymers. Many studies have been reported on the fabrication of MBG/polymer
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composites in the field of bone tissue engineering [99], but, to date, none of these constructs has been
proposed for cardiac or lung tissue engineering. In general, applications in soft tissue engineering are
dramatically scarce; only Jia et al. [100] suggested the use of MBG/chitosan composite films to induce
hemostasis and accelerate wound healing.
Crucial questions need to be addressed before clinical translation, including: How can we
minimize the nonspecific adverse effects of ions/drugs released by BG/MBG-based constructs? What is
the underlying signaling cascade of these ions on cardiac/lung tissue regeneration? How can we
combine advanced materials and stem cell sciences for new bone regenerative engineering?
Another aspect that deserves to be mentioned is the risk of soft tissue calcification: While the
formation of a surface apatite layer (bioactivity) is key to generate a strong interfacial bond between
BG and bone, this phenomenon should be avoided when BGs are put in contact with cardiac and lung
tissues or, in general, soft organs of the body.
Lastly, it will be crucial for developing constructs that can be easy-to-handle for surgeons and
other clinical staff directly involved in their possible use and commercialization.
5. Conclusions
Taken together, BGs have achieved great interest in soft tissue engineering strategies over the
recent years. The excellent biocompatibility, the ability to bond to living tissues, the antimicrobial
properties and the ability to induce angiogenesis are considered as desirable characteristics of BGs to
use in regenerative medicine [40]. Given these features, BGs are being currently used experimentally
for soft tissue regeneration to find a way to use them clinically [101]. Up to now, most of these studies
have been conducted on the skin and nerve tissues with satisfactory results [102–105]. Furthermore, the
use of melt-derived and sol-gel BGs in the repair and regeneration of cardiac and lung tissues has also
been reported with early promising results [73–76,83–90]. In this pioneering set of studies, BGs have
been usually incorporated in polymeric matrices that match better the physico-mechanical properties
of soft and delicate cardiac/lung tissues. Looking at the future, mesoporous BGs (MBGs) could be
highly interesting platforms for the controlled release of therapeutic agents eliciting beneficial effects
to injured heart and lungs [106]. MBGs could be indeed added to various biodegradable polymers
to improve the functionality of the cardiac patches as well as to deliver desirable drugs and growth
factors for accelerating regeneration. Overall, more research is needed to reveal all the aspects around
the application of BGs in contact with these highly important tissues.
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